Guerbet: 2015 annual revenue
11 February 2016 - 5:02AM
Excellent level of activity in
2015
€449.4 million in revenue: +10.0% at constant
exchange rates
VILLEPINTE, France, Feb. 10, 2016 (GLOBE
NEWSWIRE) -- Guerbet (FR0000032526 GBT), a global
specialist in contrast agents and medical imaging solutions, is
reporting €460.8 million in revenue for financial year 2015,
representing a 12.7% increase on a like-for-like basis. At constant
exchange rates, revenue grew by 10.0% to €449.4 million.
Consolidated Group revenue excluding
integration of CMDS (IFRS)
In millions of euros |
Financial year 2015 |
Financial year 2014 |
Change |
Q4 2015 |
Q4 2014 |
Change |
Sales in Europe |
318.5 |
289.3 |
10.1% |
81.7 |
74.3 |
10.0% |
Sales
in Other Markets |
142.3 |
119.7 |
18.9% |
35.4 |
32.1 |
10.1% |
Total |
460.8 |
409.0 |
12.7% |
117.1 |
106.4 |
10.0% |
Very good activity in the fourth
quarter: €117.1 million In the 4th quarter 2015, the 10.0%
growth was virtually identical in Europe and in the rest of the
world. This increase was mainly related to the performance of
Dotarem® and Lipiodol®, gaining 9.6% at
constant exchange rates.
Strong sales growth in 2015: +12.7%
Nearly all countries contributed to the Group's
growth The increase in revenue in Europe can be
seen in nearly all countries. At constant exchange rates, its
revenue for the European region grew by 9.0%. The markets outside
Europe experienced strong growth at +18.9% (+14.5% at constant
exchange rates) mainly under the effect of the Group's good level
of sales in the US, South Korea, and with Latin American and Asian
distributors.
Strong performance of the four business
segments Like in financial year 2014, the four business
segments saw growth again in 2015.
Driven by Dotarem, the MRI segment grew
the most in absolute value with a 21.7% increase. With €204.8
million in revenue, this segment now represents the majority of the
Group's product mix, accounting for 44.4% of sales.
The X-ray segment increased by 1.9% to €191.4
million. Sales benefited from a favourable volume effect from
Xenetix®.
With steady sales for Lipiodol and
Patent Blue V, the IRT segment continued to rise
considerably at a rate of more than 40% over the financial
year.
The Imaging Solutions and Services (ISS) segment
saw 3.8% growth, with sales amounting to €17.9 million.
Integration of the "CMDS" activity starting
from 1 December 2015 The final acquisition of Mallinckrodt's
"contrast media and delivery systems" (CMDS) activity was concluded
on 27 November 2015. Starting from 1 December 2015, the Group now
incorporates this activity, giving priority to curbing the decline
in sales of more than 15% for the last two years. For December,
"CMDS" revenue amounted to €27.9 million.
2016, a year of transition for the Group
2016 will be marked by the integration of the "CMDS" activity. In
order to ensure a successful integration as soon as possible, the
Group has chosen to modify its sales structures and reposition its
product offering. Beyond the commercial challenge, activity in 2016
will be marked by the Group's efforts necessary to quickly
integrate the "CMDS" employees, harmonize the company cultures,
align the information systems and redefine the industrial and
operational strategies in order to deliver the expected
synergies.
Upcoming events:
- Publication of 2015 annual results on 14 April 2016 before
trading
About Guerbet
With nearly 90 years' experience, Guerbet is a pioneer in the
contrast agent field and the global specialist of the medical
imaging market. It offers a comprehensive range of X-Ray, Magnetic
Resonance Imaging (MRI) and Interventional Radiology and
Theranostics (IRT) products, along with a range of injectors and
related medical devices to improve the diagnosis and treatment of
patients. The acquisition of Mallinckrod's "contrast media and
delivery systems" (CMDS) activity has doubled its size with an
expanded offering. In 2014, the combined pro forma sales of Guerbet
and the CMDS activity represented approximately €800 million, with
around 2,500 employees. Guerbet (GBT) is listed on NYSE Euronext
Paris (Segment B - Mid Caps).
For more information about Guerbet,
please visit www.guerbet.com
Contacts
Jean-François Le
Martret Chief Financial Officer 01 45 91 50 00
|
Christophe de
Lylle/Benjamin Lehari 01 56 88 11 11
cdelylle@actifin.fr/blehari@actifin.fr Press Jennifer
Jullia 01 56 88 11 19 jjullia@actifin.fr |
Press release http://hugin.info/159769/R/1985322/728063.pdf
HUG#1985322
Guerbet (EU:GBT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Guerbet (EU:GBT)
Historical Stock Chart
From Jul 2023 to Jul 2024